LPA and atherosclerosis: Nevertheless, some societal guidelines highlight that universal screening carries likely little harm and identification of patients with extremely high Lp(a) levels ≥ 180 mg/dL (≥ 430 nmoL/L) is important as these individuals have lifetime ASCVD risk similar to patients with HeFH [33].